Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

NCT00880399 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00880399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00880399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
March 1, 2009
Completion date
June 16, 2010
Enrollment
328 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major